What cut-off value has the American Academy of Pediatrics set for treatment with intravenous glucose in infants with symptomatic hypoglycemia?

Enhance your readiness for the MEDNAX Neonatal Nurse Practitioner Exam. Utilize flashcards, multiple-choice questions, and detailed explanations. Equip yourself for success!

Multiple Choice

What cut-off value has the American Academy of Pediatrics set for treatment with intravenous glucose in infants with symptomatic hypoglycemia?

Explanation:
The main concept here is the treatment threshold for symptomatic neonatal hypoglycemia. The American Academy of Pediatrics advocates treating infants who have symptoms of hypoglycemia when their blood glucose falls to or below 40 mg/dL. This cut-off is chosen to rapidly restore cerebral glucose and prevent neurologic injury, since the brain is highly vulnerable to energy failure in the immediate newborn period. In practice, when a symptomatic infant has a glucose level at or below 40 mg/dL, an intravenous bolus of dextrose is given to quickly raise the glucose, followed by a maintenance infusion and close monitoring to keep levels above the threshold. The other numeric values (35, 45, 50) reflect different contexts or guidelines and are not the standard treatment cutoff for symptomatic cases per AAP.

The main concept here is the treatment threshold for symptomatic neonatal hypoglycemia. The American Academy of Pediatrics advocates treating infants who have symptoms of hypoglycemia when their blood glucose falls to or below 40 mg/dL. This cut-off is chosen to rapidly restore cerebral glucose and prevent neurologic injury, since the brain is highly vulnerable to energy failure in the immediate newborn period.

In practice, when a symptomatic infant has a glucose level at or below 40 mg/dL, an intravenous bolus of dextrose is given to quickly raise the glucose, followed by a maintenance infusion and close monitoring to keep levels above the threshold. The other numeric values (35, 45, 50) reflect different contexts or guidelines and are not the standard treatment cutoff for symptomatic cases per AAP.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy